Cytori Therapeutics announced that Cytori Cell Therapy™ was approved for clinical use to treat knee osteoarthritis at the Tokyo Osteoarthritis Clinic under the Japanese Act on the Safety of Regenerative Medicine.
The approval is limited to facilities under the clinic’s umbrella and does not restrict the number of patients that can be treated. The approval is not reimbursed by Japan’s healthcare system, and patients will be responsible for the costs.
In the Japanese orthopaedic market, large joint reconstruction is the dominant segment. Learn more about the region from ORTHOWORLD’s intelligence report, The Japanese Orthopaedic Market.
Cytori Therapeutics announced that Cytori Cell Therapy™ was approved for clinical use to treat knee osteoarthritis at the Tokyo Osteoarthritis Clinic under the Japanese Act on the Safety of Regenerative Medicine.
The approval is limited to facilities under the clinic’s umbrella and does not restrict the number of patients that can be treated....
Cytori Therapeutics announced that Cytori Cell Therapy™ was approved for clinical use to treat knee osteoarthritis at the Tokyo Osteoarthritis Clinic under the Japanese Act on the Safety of Regenerative Medicine.
The approval is limited to facilities under the clinic’s umbrella and does not restrict the number of patients that can be treated. The approval is not reimbursed by Japan’s healthcare system, and patients will be responsible for the costs.
In the Japanese orthopaedic market, large joint reconstruction is the dominant segment. Learn more about the region from ORTHOWORLD’s intelligence report, The Japanese Orthopaedic Market.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
